<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245427</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A-6012</org_study_id>
    <nct_id>NCT00245427</nct_id>
  </id_info>
  <brief_title>Outcomes of Patients Not Responding to Antibiotics in the Community</brief_title>
  <official_title>Outcomes of Patients Not Responding to Outpatient Macrolide or b-Lactam Therapy for the Treatment of Community Acquired Pneumonia: Expansion to Include Acute Exacerbations of Chronic Bronchitis and Acute Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CPL Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CPL Associates</source>
  <brief_summary>
    <textblock>
      A study to report the outcomes of patients who fail to respond to beta-lactam and macrolide
      antibiotics in the community
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To document and describe the clinical, microbiological, and pharmacoeconomic outcomes of two
      hundred patients who failed to respond to outpatient macrolide or beta-lactam therapy.
      Evaluable patients must have a positive culture obtained after they failed their initial
      macrolide or beta-lactam. The isolated pathogen must have a known MIC to the antibiotic class
      they failed to respond to (i.e. macrolide or b-lactam). The isolate must be available to be
      sent to the central laboratory for MIC testing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>varies</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK/PD pharmacoeconomics</measure>
    <time_frame>varies</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Sinusitis</condition>
  <condition>Bronchitis, Chronic</condition>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>1 All macrolide antibiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 All beta lactam antibiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all macrolide antibiotics</intervention_name>
    <description>Varies based on antibiotic</description>
    <arm_group_label>1 All macrolide antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all beta-lactam antibiotics</intervention_name>
    <description>Varies based on antibiotic</description>
    <arm_group_label>2 All beta lactam antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who have failed to respond to at least three (ABECB and CAP) or five
        (AMS/ABRS/AECRS) days of macrolide or b-lactam therapy meeting all of the protocol criteria
        for acute bacterial exacerbations on chronic bronchitis(ABECB), community acquired
        pneumonia(CAP) and acute maxillary sinusitis(AMS) will be eligible for enrollment. All
        patients, whether enrolled retrospectively or concurrently, must have a positive culture.
        The pathogenic bacteria must be identified by a local laboratory and have a known
        susceptibility to the antibiotic class the patient failed to respond to (i.e. macrolide or
        b-lactam). The isolate must be sent to the Study Coordinating Center for precise MIC
        determination.

        Exclusion Criteria:

        Patients presenting with any of the following will not be included in the study:

          1. Life expectancy &lt;3 months from underlying disease

          2. Underlying lung carcinoma

          3. Cystic fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome J Schentag, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of NY at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Paladino, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>State University of NY at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deaconess Medical School</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cplassociates.com</url>
  </link>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>October 29, 2007</last_update_submitted>
  <last_update_submitted_qc>October 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2007</last_update_posted>
  <keyword>beta-lactam</keyword>
  <keyword>macrolide</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

